Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 8%
Hold 50%
Sell 8%
Strong Sell 0%

Bulls say

Pfizer is a leading global pharmaceutical company with a strong portfolio of prescription drugs and vaccines, and a significant presence in emerging markets. While the recent underperformance of the stock may pose a near-term challenge, Pfizer has a solid value proposition with potential upside driven by key assets such as Vyndaqel, which has the potential to generate $6 billion in peak sales. Additionally, the company's commitment to shareholder returns and a strong pipeline of new growth drivers further support a positive outlook for the stock.

Bears say

Pfizer is currently facing a number of challenges that could potentially impact its stock price and overall financial performance. These include a slower growth profile, higher exposure to loss of exclusivity for certain products, and a lower than average dividend payout ratio, which could limit the company's flexibility for mergers and acquisitions. Additionally, Pfizer is facing sustainability concerns related to access to medicines in lower income countries and potential environmental impacts from its manufacturing operations. These challenges could lead to a contraction in the company's price-to-earnings multiple and result in downside risks to its stock price.

Pfizer (PFE) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 8% recommend Buy, 50% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Buy based on their latest research and market trends.

According to 12 analysts, Pfizer (PFE) has a Buy consensus rating as of Jun 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.